Valuation: Insmed Incorporated

Market Cap 28.93B 25.03B 23.37B 21.44B 40.33B 2,754B 40.97B 274B 108B 1,380B 109B 106B 4,563B P/E 2026 *
-54.3x
P/E 2027 * 149x
Enterprise Value 28.26B 24.44B 22.83B 20.94B 39.38B 2,689B 40.01B 268B 105B 1,348B 106B 104B 4,456B EV / Sales 2026 *
15.9x
EV / Sales 2027 * 9.7x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.92%
1 week+33.25%
Current month+33.25%
1 month+16.43%
3 months+25.12%
6 months-12.14%
Current year-24.51%
1 week 96.42
Extreme 96.42
137.7
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%+33.25%+20.20%+500.73% 28.73B
+8.49%+23.38%+65.44%+104.90% 62.92B
+1.25%+2.44%+32.55%+72.63% 54.32B
+2.63%+3.13%-16.11%-5.16% 22.91B
+10.83%+21.32%+45.03%+2.02% 21.65B
+6.50%+7.56%+38.20%-21.33% 17.76B
-3.88%+20.98%+201.07%+350.94% 16.47B
+6.20%+12.16%+28.51%+629.05% 15.48B
+2.79%+0.62%+42.71%+163.51% 13.12B
+1.59%+3.13%+443.59%+183.35% 12.12B
Average +3.54%+6.51%+90.12%+198.06% 26.55B
Weighted average by Cap. +4.04%+9.41%+65.70%+167.11%

Financials

2026 *2027 *
Net sales 1.77B 1.53B 1.43B 1.31B 2.47B 169B 2.51B 16.81B 6.6B 84.61B 6.66B 6.51B 280B 2.85B 2.46B 2.3B 2.11B 3.97B 271B 4.03B 26.98B 10.59B 136B 10.69B 10.46B 449B
Net income -537M -464M -434M -398M -748M -51.08B -760M -5.09B -2B -25.6B -2.02B -1.97B -84.63B 122M 105M 98.19M 90.08M 169M 11.57B 172M 1.15B 452M 5.8B 456M 446M 19.17B
Net Debt -676M -585M -546M -501M -942M -64.32B -957M -6.41B -2.51B -32.24B -2.54B -2.48B -107B -1.12B -973M -909M -834M -1.57B -107B -1.59B -10.66B -4.18B -53.67B -4.22B -4.13B -177B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-07 US$131.24 -0.99% 3,062,610
26-08-06 US$132.55 +33.86% 12,036,146
26-08-05 US$99.02 +0.27% 4,899,602
26-08-04 US$98.75 +0.30% 4,290,804
26-08-03 US$98.45 -0.15% 3,546,860
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
132.55USD
Average target price
197.82USD
Spread / Average Target
+49.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock